RBC Capital analyst Simos Simeonidis reiterated a Sector Perform rating and boosted his price target on Sarepta Therapeutic (NASDAQ: SRPT) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Sarepta Therapeutic (SRPT) PT Raised to $47 at Baird; Increasingly Bullish on Risk/RewardAugust 7, 2015 7:41 AM SunTrust Downgrades Sarepta Therapeutic (SRPT) to NeutralAugust 7, 2015 7:07 AM Sarepta Therapeutics (SRPT) Tops Q2 EPS by 20cAugust 6, 2015 7:35 AM